Health Research Methods, Evidence, and Impact


Barbara Schmidt

MD (Georg-August), PhD (Georg August), MSc(McMaster), FRCPC

Professor (Part-time), Dept of Health Research Methods, Evidence, and Impact

Associate Editor, ACP Journal Club

905.521.2100 x 40748
905.577.1427
schmidt@mcmaster.ca

Neonatal Trials Group
DBCVSRI Level 4, C4-109
Hamilton General Hospital Campus
237 Barton Street East
Hamilton, ON  L8L 2X2

 

 

Academic Interests

Dr. Barbara Schmidt is a pediatrician and staff neonatologist at the Hamilton Health Sciences. Currently Dr. Schmidt is focusing on large neonatal randomized trials with clinically important long-term outcomes such as growth and development. Apart from her clinical practice in neonatal intensive care and research, Dr. Schmidt is also actively involved in teaching.

Selected Publications

  1. Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV, Davis PG, Tin W, Moddemann D, Solimano A, Ohlsson A, Barrington KJ, Roberts RS; Caffeine for Apnea of Prematurity (CAP) Trial Investigators.  Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012 Jan 18; 307(3):275-82.
  2. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, for the Caffeine for Apnea of Prematurity Trial Group: Long-term effects of caffeine therapy for apnea of prematurity.  N Engl J Med 2007;357:1893-1902.
  3. Barbara Schmidt, M.D., Robin S. Roberts, M.Sc., Peter Davis, M.D., Lex W. Doyle, M.D., Keith J. Barrington, M.D., Arne Ohlsson, M.D., Alfonso Solimano, M.D., Win Tin, M.D., for the Caffeine for Apnea of Prematurity Trial Group. Caffeine Therapy for Apnea of Prematurity. NEJM 2006:354:2112-2121
  4. Millar, D, Schmidt B. Controversies surrounding xanthine therapy. Seminars in Neonatology 2004, 9:239-244.
  5. Schmidt B, Asztalos EV, Roberts RS, Robertson CMT, Sauve RS, Whitfield MF for the Trial of Indomethacin Prophylaxis in Preterms Investigators. Impact of Bronchopulmonary Dysplasia, Brain Injury, and Severe Retinopathy on the Outcome of Extremely Low-Birth-Weight Infants at 18 Months. Results From the Trial of Indomethacin Prophylaxis in Preterms. JAMA 2003; 289:1124-1129.
  6. Zhang B, Schmidt B. Do we measure the right endpoints? A systematic review of primary outcomes in recent neonatal randomized clinical trials. J of Pediatr, 2001; 138:76-80.
  7. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts R, Saigal S, Solimano A, Vincer M, Wright L, for the TIPP investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med, 2001; 344:1966-1972.
  8. Schmidt B, Gillie P, Caco C, Roberts J, Roberts R. Do sick newborn infants benefit from participation in a randomized clinical trial? J Pediatr 1999;134:151-155.

Search for citations for Dr. Schmidt on PubMed